Evidence map›Paper›PMID 42206288›Full record

ReviewJournal of Taibah University Medical Sciences2026

Osteoarthritis and rheumatoid arthritis: A comparative review of pathophysiology, diagnosis and evolving management.

Shriyeta Biswas, Juganta K Kalita, Bedaparna Nath, N Anirudh Singh, Md Sarowar Hossain, Saikat Sen

Abstract readReview
In one paragraph

Review in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shriyeta BiswasFaculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.
Juganta K KalitaFaculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.
Bedaparna NathFaculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.
N Anirudh SinghFaculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.
Md Sarowar HossainFaculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.
Saikat SenFaculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA) and rheumatoid arthritis (RA) are among the leading causes of chronic joint pain and disability, resulting in significant healthcare and economic burdens. OA is a degenerative disorder characterized by cartilage degradation, whereas RA is an autoimmune condition that leads to synovial inflammation. Despite their differences, both conditions share similar symptoms such as joint pain, stiffness, and functional decline, which can complicate early diagnosis and delay targeted treatment. Degradation of the extracellular matrix, chondrocyte senescence, and responses to biomechanical stress are considered key molecular events in OA. By contrast, RA is driven by abnormal immune activation, autoantibody production, and ongoing synovial inflammation. This review provides a comparative analysis of OA and RA, focusing on pathophysiology, diagnostic modalities, clinical assessment frameworks, and evolving management strategies. Diagnostic strategies that combine patient evaluation, advanced imaging techniques, and emerging molecular biomarkers to improve early detection are also discussed. Critical evaluations are provided of management strategies that encompass pharmacologic treatments, such as using nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, biologics, and Janus kinase (JAK) inhibitors, as well as non-pharmacologic interventions, including physical therapy, lifestyle modifications, and surgical options. In addition, the limited disease-modifying options for OA and safety concerns with long-term immunosuppressive therapy in RA are noted, highlighting the need for biomarker guided personalized therapies.

Indexed as

Autoimmune conditionDegenerative disorderInflammationPainTreatment

Identifiers

PMID42206288
PMCPMC13207567

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.